Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FDA perspective on peptide formulation and stability issues

C H Niu1, Y Y Chiu

  • 1Office of New Drug Chemistry, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Parklawn Building, Room 14B-45 5600 Fishers Lane, Rockville, Maryland 20857, USA.

Journal of Pharmaceutical Sciences
|November 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A sudden change and recovery in the magnetic environment around a repeating fast radio burst.

Science (New York, N.Y.)·2026
Same author

Author Correction: A fast radio burst source at a complex magnetized site in a barred galaxy.

Nature·2022
Same author

A fast radio burst source at a complex magnetized site in a barred galaxy.

Nature·2022
Same author

Author Correction: A bimodal burst energy distribution of a repeating fast radio burst source.

Nature·2021
Same author

A bimodal burst energy distribution of a repeating fast radio burst source.

Nature·2021
Same author

No pulsed radio emission during a bursting phase of a Galactic magnetar.

Nature·2020
Same journal

Enhanced zika virus suppression by coupling ribavirin with biodegradable drug delivery.

Journal of pharmaceutical sciences·2026
Same journal

Immune tolerance platforms to mitigate unwanted immune responses.

Journal of pharmaceutical sciences·2026
Same journal

Green, renewable, or low-carbon? A framework for informed solvent selection in pharmaceutical sciences.

Journal of pharmaceutical sciences·2026
Same journal

Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI.

Journal of pharmaceutical sciences·2026
Same journal

Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation.

Journal of pharmaceutical sciences·2026
Same journal

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Journal of pharmaceutical sciences·2026
See all related articles

Novel peptide drug delivery systems aim to overcome the limitations of traditional daily injections. These advanced methods offer improved patient compliance through prolonged, targeted, or pulsatile drug action, with several FDA-approved options available.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Delivery Systems
  • Biotechnology

Background:

  • Traditional peptide drug administration involves daily sterile injections, leading to patient discomfort and poor adherence.
  • Patient non-compliance with injectable peptide therapeutics necessitates the development of alternative drug delivery strategies.
  • Existing delivery methods present challenges in achieving prolonged, localized, or pulsatile therapeutic effects.

Purpose of the Study:

  • To review novel peptide drug delivery systems designed to enhance patient compliance and therapeutic outcomes.
  • To explore various advanced dosage forms for peptide drugs, including oral, nasal, and controlled-release injectables.
  • To discuss the unique characteristics and regulatory considerations associated with these innovative delivery systems.

Main Methods:

Related Experiment Videos

  • Literature review of recent advancements in peptide drug delivery technologies.
  • Analysis of FDA-approved novel peptide drug formulations.
  • Comparative assessment of different delivery routes (oral, nasal, injectable) and their properties.

Main Results:

  • Several novel peptide drug delivery systems have been recently approved by the FDA.
  • These systems offer alternatives to daily injections, improving patient convenience and compliance.
  • Various approaches provide prolonged, localized, or pulsatile drug release profiles.

Conclusions:

  • Innovative peptide drug delivery systems are crucial for improving therapeutic efficacy and patient acceptance.
  • Oral, nasal, and long-acting injectable formulations represent significant advancements in peptide drug administration.
  • Understanding the characteristics and regulatory landscape is key to the successful implementation of these novel systems.